{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:18:55Z","timestamp":1782602335094,"version":"3.54.5"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":3371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1093\/annonc\/mdq290","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T07:47:43Z","timestamp":1287474463000},"page":"vii72-vii80","source":"Crossref","is-referenced-by-count":90,"special_numbering":"S7","title":["Gastrointestinal neuroendocrine tumors"],"prefix":"10.1016","volume":"21","author":[{"given":"K.E.","family":"\u00d6berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq290_bb0010","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u2018carcinoid\u2019: epidemiology of and prognostic factors for neuroendocrine tumors in 35825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0015","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.23883","article-title":"Neuroendocrine tumor epidemiology: contrasting Norway and North America","volume":"113","author":"Hauso","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq290_bb0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.sla.0000129342.67174.67","article-title":"Updated population-based review of carcinoid tumors","volume":"240","author":"Maggard","year":"2004","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mdq290_bb0025","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"5-decade analysis of 13715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq290_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0035","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1053\/j.gastro.2008.05.047","article-title":"Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors","volume":"135","author":"Metz","year":"2008","journal-title":"Gastroenterology"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdq290_bb0040","first-page":"iv1","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours","volume":"54","author":"Ramage","year":"2005","journal-title":"Gut"},{"key":"10.1093\/annonc\/mdq290_bb0045","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1515\/CCLM.1998.147","article-title":"Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours","volume":"36","author":"Pirker","year":"1998","journal-title":"Clin Chem Lab Med"},{"key":"10.1093\/annonc\/mdq290_bb0050","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000162876","article-title":"Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors","volume":"89","author":"Korse","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1093\/annonc\/mdq290_bb0055","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8","article-title":"Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors","volume":"86","author":"Bajetta","year":"1999","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq290_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0065","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/02841860310010547","article-title":"Carcinoid\u2013a comprehensive review","volume":"42","author":"Schnirer","year":"2003","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000111034","article-title":"Consensus guidelines for the management of patients with digestive neuroendocrine tumors\u2013well-differentiated jejunal-ileal tumor\/carcinoma","volume":"87","author":"Eriksson","year":"2008","journal-title":"Neuroendocrinology"},{"key":"10.1093\/annonc\/mdq290_bb0075","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/ERC-08-0017","article-title":"Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours","volume":"15","author":"Pape","year":"2008","journal-title":"Endocr Relat cancer"},{"key":"10.1093\/annonc\/mdq290_bb0080","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000098012","article-title":"Well-differentiated pancreatic nonfunctioning tumors\/carcinoma","volume":"84","author":"Falconi","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.1093\/annonc\/mdq290_bb0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0720-048X(00)00187-X","article-title":"Standardisation of imaging in neuroendocrine tumours: results of a European delphi process","volume":"37","author":"Ricke","year":"2001","journal-title":"Eur J Radiol"},{"key":"10.1093\/annonc\/mdq290_bb0090","first-page":"426","article-title":"Karzenoide Tumoren des D\u00fcnndarms","volume":"1","author":"Oberndorfer","year":"1907","journal-title":"Frankf Zschr Pathol"},{"key":"10.1093\/annonc\/mdq290_bb0095","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(63)90951-6","article-title":"The classification of carcinoid tumours","volume":"1","author":"Williams","year":"1963","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq290_bb0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1196\/annals.1294.002","article-title":"The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification","volume":"1014","author":"Kloppel","year":"2004","journal-title":"Ann NY Acad Sci"},{"key":"10.1093\/annonc\/mdq290_bb0105","unstructured":"TNM classification of malignant tumoursInternational Union Against Cancer. Available at: http:\/\/www.uiccorg\/tnm 2010"},{"key":"10.1093\/annonc\/mdq290_bb0110","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system","volume":"449","author":"Rindi","year":"2006","journal-title":"Virchows Arch"},{"key":"10.1093\/annonc\/mdq290_bb0115","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1093\/annonc\/mdq290_bb0120","first-page":"113","article-title":"Biology and treatment of metastatic gastrointestinal neuroendocrine tumors","volume":"2","author":"Strosberg","year":"2008","journal-title":"Gastrointest Cancer Res"},{"key":"10.1093\/annonc\/mdq290_bb0125","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","volume":"25","author":"Kaltsas","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1093\/annonc\/mdq290_bb0130","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0135","article-title":"Health-related quality of life of patients with neuroendocrine tumor compared to the United States general population","author":"Beaumont","year":"2009","journal-title":"NANETS, abstract"},{"key":"10.1093\/annonc\/mdq290_bb0140","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0002-9610(05)80529-X","article-title":"Biology and management of the midgut carcinoid","volume":"165","author":"Basson","year":"1993","journal-title":"Am J Surg"},{"key":"10.1093\/annonc\/mdq290_bb0145","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","volume":"340","author":"Kulke","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mdq290_bb0150","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000085237","article-title":"Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)","volume":"80","author":"Plockinger","year":"2004","journal-title":"Neuroendocrinology"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdq290_bb0155","doi-asserted-by":"crossref","first-page":"ii104","DOI":"10.1093\/annonc\/mdn117","article-title":"Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Oberg","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0160","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.cgh.2005.12.008","article-title":"Therapeutic options for gastrointestinal carcinoids","volume":"4","author":"Modlin","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1093\/annonc\/mdq290_bb0165","first-page":"1091","article-title":"Cytoreductive hepatic surgery for neuroendocrine tumors","volume":"108","author":"McEntee","year":"1990","journal-title":"Surgery"},{"key":"10.1093\/annonc\/mdq290_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0005-2736(03)00235-9","article-title":"Somatostatin receptors","volume":"1616","author":"Moller","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1093\/annonc\/mdq290_bb0175","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdq290_bb0180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","article-title":"Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors","volume":"80","author":"Schmid","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1093\/annonc\/mdq290_bb0185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): development, mechanism of action and potential applications","volume":"286","author":"Schmid","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1093\/annonc\/mdq290_bb0190","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mdq290_bb0195","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJM198511073131916","article-title":"Rapid reversal of carcinoid crisis with a somatostatin analogue","volume":"313","author":"Kvols","year":"1985","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mdq290_bb0200","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-2036.2003.01420.x","article-title":"Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience","volume":"17","author":"Garland","year":"2003","journal-title":"Alimentary Pharmacol Ther"},{"key":"10.1093\/annonc\/mdq290_bb0205","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1510107","article-title":"High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours","volume":"151","author":"Welin","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1093\/annonc\/mdq290_bb0210","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2165\/00003495-198938050-00002","article-title":"A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion","volume":"38","author":"Battershill","year":"1989","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdq290_bb0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM198501033120104","article-title":"Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera","volume":"312","author":"Maton","year":"1985","journal-title":"New Engl J Med"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdq290_bb0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000201070","article-title":"Pharmacodynamic effects of sandostatin in the gastrointestinal tract","volume":"54","author":"Gyr","year":"1993","journal-title":"Digestion"},{"key":"10.1093\/annonc\/mdq290_bb0225","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1007\/BF01300194","article-title":"Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel","volume":"32","author":"Dueno","year":"1987","journal-title":"Dig Dis Sci"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdq290_bb0230","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000201396","article-title":"Somatostatin receptor imaging: predictive and prognostic considerations","volume":"57","author":"Anthony","year":"1996","journal-title":"Digestion"},{"key":"10.1093\/annonc\/mdq290_bb0235","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1677\/ERC-07-0288","article-title":"Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms","volume":"15","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1093\/annonc\/mdq290_bb0240","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/annonc\/mdj113","article-title":"Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma","volume":"17","author":"Panzuto","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0245","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q","article-title":"Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors","volume":"72","author":"Saltz","year":"1993","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq290_bb0250","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0255","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoma syndrome; results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1093\/annonc\/mdq290_bb0260","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Alimentary Pharmacol Ther"},{"key":"10.1093\/annonc\/mdq290_bb0265","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0270","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000421-200008000-00020","article-title":"Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors","volume":"23","author":"Ricci","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0275","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2265.1989.tb00436.x","article-title":"Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201\u2013995)","volume":"30","author":"Wynick","year":"1989","journal-title":"Clin Endocrinol"},{"key":"10.1093\/annonc\/mdq290_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jcem-73-1-1","article-title":"Clinical review 23: the use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors","volume":"73","author":"Wynick","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdq290_bb0285","article-title":"Safety and efficacy of pasireotide (SOM230) in patientes with metastatic carcinoid tumors refractory or resistant to octreotide LAR. Results of a phase II study","author":"Kvols","year":"2006","journal-title":"ASCO annual Meeting Abstract"},{"key":"10.1093\/annonc\/mdq290_bb0290","first-page":"152","article-title":"Neuroendocrine tumors: is there a standard treatment?","volume":"2","author":"Kulke","year":"2008","journal-title":"Gastrointest Cancer Res"},{"key":"10.1093\/annonc\/mdq290_bb0295","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq290_bb0300","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0305","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0310","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq290_bb0315","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1093\/annonc\/mdq290_bb0320","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"Kolby","year":"2003","journal-title":"Br J Surg"},{"key":"10.1093\/annonc\/mdq290_bb0325","article-title":"Updated results of the phase III trial of sunitinib v.s. placebo for treatment of advanced pancreatic neuroendocrine tumors","author":"Raymond","year":"2010","journal-title":"ASCO GI"},{"key":"10.1093\/annonc\/mdq290_bb0330","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.beem.2007.01.007","article-title":"Neuroendocrine tumors. Peptide receptor radionuclide therapy","volume":"21","author":"Forrer","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdq290_bb0335","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","article-title":"Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"36","author":"Valkema","year":"2006","journal-title":"Semin Nucl Med"},{"key":"10.1093\/annonc\/mdq290_bb0340","doi-asserted-by":"crossref","unstructured":"Sobin LH, Wittekind. C (eds) 2002 TNM Classification of Malignant Tumours. Wibey-Liss: New York","DOI":"10.1002\/0471463752"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419396978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419396978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/suppl_7\/vii72\/19446207\/mdq290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T13:48:28Z","timestamp":1711892908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419396978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":67,"alternative-id":["S0923753419396978"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq290","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}